Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.030 +0.065 (+6.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
30 31 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor
Via Investor Brand Network
Topics Intellectual Property
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter
Via Investor Brand Network
Topics Economy Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter
Via CannabisNewsWire
Topics Economy Intellectual Property
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients
Via Investor Brand Network
Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International Portfolio
Via Investor Brand Network
Topics Intellectual Property
Lexaria Receives First Granted Patent in Canada
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
Lexaria’s Human Oral Nicotine Study Begins Dosing
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication
Via Investor Brand Network
Topics Intellectual Property
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
Via ACCESSWIRE
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback